NCT06660511 2024-10-28
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Second Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Recruiting